Seegene Posts 474.2 Billion Won in Sales and 34.5 Billion Won in Operating Profit Last Year, Returning to Profitability

Non-respiratory product group maintains robust growth

On February 25, Seegene announced via a regulatory filing that, backed by solid sales growth in its key product lines, it returned to an operating profit in the fourth quarter of last year, continuing its trend of profitability recovery.

According to its preliminary consolidated results under Korean International Financial Reporting Standards (K-IFRS), Seegene’s sales in the fourth quarter of last year reached 130.6 billion won, up 13.3% year-on-year and 15.0% quarter-on-quarter. Operating profit came to 6.9 billion won, marking a turnaround from an operating loss a year earlier. On a cumulative full-year basis, the company posted sales of 474.2 billion won and operating profit of 34.5 billion won, also achieving a turnaround to profitability for the year as a whole.

Seegene stated that in the fourth quarter, its non-respiratory product group maintained robust growth, while the respiratory product group also showed signs of recovery. Sales of the non-respiratory syndromic product group increased by 24.4% compared with the same period a year earlier. Syndromic testing is a next-generation molecular diagnostic method that uses a single sample to simultaneously test for multiple pathogens, thereby enhancing diagnostic efficiency and clinical utility. The non-respiratory syndromic product group includes human papillomavirus (HPV) products, gastrointestinal (GI) products, and sexually transmitted infection (STI) products.

For the respiratory product group, demand recovered in the fourth quarter, leading to an overall improvement trend. The company added that it is maintaining a solid sales base in the European market, while continuously seeking expansion opportunities in major markets around the world.

Together with improved global sales performance of its key products, Seegene is also focusing on advancing its data-driven testing and automation strategies. The company is working to strengthen its diagnostic operations system by linking STAgora™, which connects and provides statistical data on PCR test results worldwide to enable real-time understanding of disease trends, with CURECA™, a fully unmanned automation system that automates the entire PCR testing process.

The company believes that building a standardized unmanned testing process based on automation and enhancing data utilization are key elements for expanding its mid- to long-term growth foundation. Through CURECA, it aims to improve laboratory operational efficiency, and through STAgora, it plans to analyze and share accumulated statistical data in real time, thereby expanding the range of applications for PCR test results. Seegene plans to present the current progress and future direction related to STAgora and CURECA on the global stage, including at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in April and the Association for Diagnostics & Laboratory Medicine (ADLM) in the United States in July.

Kim Jungyong, Head of Finance Management at Seegene, said, “As growth continues across our major diagnostic segments, our sales base is expanding in a stable manner, and the trend of profitability improvement is also ongoing. This year, leveraging major global conferences as momentum, we plan to share our roadmap for STAgora and CURECA, which will change the paradigm of future testing, and to gradually improve our technologies and their scope of application based on on-site feedback and operating data.”